Catalyst Wire Dossier Catalyst Wire Dossier

Engineered CD30-targeted T cells (CAR-T)

CD30 CAR-T cells · University of Cologne
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Engineered CD30-targeted T cells (CAR-T), covering 2012-07-20 to 2012-07-20. Get the full timeline:

Most recent: Clinical Trial Update: Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides [Phase 1]

See pricing